Literature DB >> 11034948

Na(+)/H(+) exchange inhibitor cariporide attenuates cell injury predominantly during ischemia and not at onset of reperfusion in porcine hearts with low residual blood flow.

H H Klein1, S Pich, R M Bohle, S Lindert-Heimberg, K Nebendahl.   

Abstract

BACKGROUND: This study investigated whether myocardial protection by inhibition of Na(+)/H(+) exchange (NHE) occurs during ischemia and/or during reperfusion. METHODS AND
RESULTS: The left anterior descending coronary artery was occluded in 32 pigs for 60 minutes and then reperfused for 24 hours. Infarct sizes (nitroblue tetrazolium [NBT] stain, histology) were determined at the end of the experiments. An extracorporeal bypass was used to achieve a constant residual blood flow of 3 mL/min in the myocardium at risk during ischemia. The NHE-1 inhibitor cariporide or distilled water was infused into the extracorporeal bypass system. In group 1, active treatment was administered from the onset of ischemia until 10 minutes of reperfusion (n=8). In group 2, active treatment was infused during the first 30 minutes of ischemia only (n=8). The group 3 animals (n=8) received intracoronary cariporide after 45 minutes of ischemia until 10 minutes of reperfusion. The control animals (group 4, n=7) were treated similarly to group 1 animals, with the cariporide solution being replaced by distilled water. Infarct sizes of group 1 (NBT stain, 41.5+/-20%; histology, 44. 6+/-12%) and group 2 (NBT stain, 33.5+/-14%; histology 34.9+/-15%) differed significantly (at least P:=0.012) from infarct sizes of group 3 (NBT stain, 71.6+/-15%; histology, 69.2+/-12%) and the control group (NBT stain, 76+/-9%; histology 72.4+/-12%). Cariporide treatment in group 1 and group 2 significantly improved functional recovery after 24 hours of reperfusion.
CONCLUSIONS: Myocardial protection by cariporide is predominantly achieved by NHE inhibition during ischemia and not during early reperfusion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034948     DOI: 10.1161/01.cir.102.16.1977

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

1.  Mitochondrial KATP channels participate in the limitation of infarct size by cariporide.

Authors:  Ignacio Pérez Nuñez; Juliana Fantinelli; Luisa F González Arbeláez; Susana M Mosca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-04-12       Impact factor: 3.000

2.  Critical role of the STAT3 pathway in the cardioprotective efficacy of zoniporide in a model of myocardial preservation - the rat isolated working heart.

Authors:  L Gao; J Tsun; L Sun; J Kwan; A Watson; P S Macdonald; M Hicks
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization.

Authors:  Hana E Baker; Alexander M Kiel; Samuel T Luebbe; Blake R Simon; Conner C Earl; Ajit Regmi; William C Roell; Kieren J Mather; Johnathan D Tune; Adam G Goodwill
Journal:  Basic Res Cardiol       Date:  2019-04-19       Impact factor: 17.165

Review 4.  Regulation of intracellular and mitochondrial sodium in health and disease.

Authors:  Elizabeth Murphy; David A Eisner
Journal:  Circ Res       Date:  2009-02-13       Impact factor: 17.367

Review 5.  NHE-1 inhibition: from protection during acute ischaemia/reperfusion to prevention/reversal of myocardial remodelling.

Authors:  Wolfgang J Linz; Andreas E Busch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-19       Impact factor: 3.000

Review 6.  Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction.

Authors:  Antonio Rodríguez-Sinovas; Yaser Abdallah; Hans Michael Piper; David Garcia-Dorado
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

7.  Why did the NHE inhibitor clinical trials fail?

Authors:  Elizabeth Murphy; David G Allen
Journal:  J Mol Cell Cardiol       Date:  2008-11-05       Impact factor: 5.000

8.  Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?

Authors:  Maaike Te Lintel Hekkert; Gary Newton; Dirk J Duncker; Michael D Schneider; Kathryn Chapman; Rehan Aqil; Robert Downham; Robert Yan; Daphne Merkus; Gavin Whitlock; Charlotte A L Lane; Darren Cawkill; Trevor Perrior
Journal:  Basic Res Cardiol       Date:  2021-05-20       Impact factor: 17.165

9.  SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart.

Authors:  Ven G Lim; Robert M Bell; Sapna Arjun; Maria Kolatsi-Joannou; David A Long; Derek M Yellon
Journal:  JACC Basic Transl Sci       Date:  2019-01-30

Review 10.  Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases.

Authors:  Al-Anood Al-Shamasi; Rozina Elkaffash; Meram Mohamed; Menatallah Rayan; Dhabya Al-Khater; Alain-Pierre Gadeau; Rashid Ahmed; Anwarul Hasan; Hussein Eldassouki; Huseyin Cagatay Yalcin; Muhammad Abdul-Ghani; Fatima Mraiche
Journal:  Int J Mol Sci       Date:  2021-11-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.